Literature DB >> 27159178

CLL: ibrutinib and transplantation ride together.

E Montserrat1, J Delgado1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27159178     DOI： 10.1038/bmt.2016.118

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Authors:  C S Link; R Teipel; F Heidenreich; E Rücker-Braun; M Schmiedgen; J Reinhardt; U Oelschlägel; M von Bonin; J M Middeke; A Muetherig; K Trautmann-Grill; U Platzbecker; M Bornhäuser; J Schetelig
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

Review 2.  How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?

Authors:  Constantine S Tam; Stephan Stilgenbauer
Journal:  Leuk Lymphoma       Date:  2015-02-17

3.  Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.

Authors:  Uri Rozovski; Ohad Benjamini; Preetesh Jain; Philip A Thompson; William G Wierda; Susan O'Brien; Jan A Burger; Alessandra Ferrajoli; Stefan Faderl; Elizabeth Shpall; Chitra Hosing; Issa F Khouri; Richard Champlin; Michael J Keating; Zeev Estrov
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

4.  Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.

Authors:  Martin F M de Rooij; Annemieke Kuil; Arnon P Kater; Marie José Kersten; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

5.  Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

Authors:  Peter Dreger; Hartmut Döhner; Matthias Ritgen; Sebastian Böttcher; Raymonde Busch; Sascha Dietrich; Donald Bunjes; Sandra Cohen; Jörg Schubert; Ute Hegenbart; Dietrich Beelen; Matthias Zeis; Michael Stadler; Justin Hasenkamp; Lutz Uharek; Christof Scheid; Andreas Humpe; Thorsten Zenz; Dirk Winkler; Michael Hallek; Michael Kneba; Norbert Schmitz; Stephan Stilgenbauer
Journal:  Blood       Date:  2010-07-01       Impact factor: 22.113

6.  Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Authors:  Jason A Dubovsky; Ryan Flynn; Jing Du; Bonnie K Harrington; Yiming Zhong; Benjamin Kaffenberger; Carrie Yang; William H Towns; Amy Lehman; Amy J Johnson; Natarajan Muthusamy; Steven M Devine; Samantha Jaglowski; Jonathan S Serody; William J Murphy; David H Munn; Leo Luznik; Geoffrey R Hill; Henry K Wong; Kelli K P MacDonald; Ivan Maillard; John Koreth; Laurence Elias; Corey Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Angela Panoskaltsis-Mortari; John C Byrd; Bruce R Blazar
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

7.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

Review 8.  Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia.

Authors:  Samantha M Jaglowski; John C Byrd
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

9.  Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.

Authors:  Michelle L Poon; Patricia S Fox; Barry I Samuels; Susan O'Brien; Elias Jabbour; Yvonne Hsu; Alison Gulbis; Martin Korbling; Richard Champlin; Lynne V Abruzzo; Roland L Bassett; Issa F Khouri
Journal:  Leuk Lymphoma       Date:  2014-08-04

Review 10.  Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Authors:  Peter Dreger; Johannes Schetelig; Niels Andersen; Paolo Corradini; Michel van Gelder; John Gribben; Eva Kimby; Mauricette Michallet; Carol Moreno; Stephan Stilgenbauer; Emili Montserrat
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113
View more
  1 in total

1.  The Difficult-to-Treat del 17 p Patient-A Case Report in Chronic Lymphocytic Leukemia.

Authors:  Ana-Maria Moldovianu; Ana Manuela Crisan; Zsofia Varady; Daniel Coriu
Journal:  Medicina (Kaunas)       Date:  2021-12-24       Impact factor: 2.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.